Navigation Links
Scientists identify treatable weakness in lethal form of prostate cancer

PHILADELPHIA A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

Mark Rubin, M.D., professor of pathology and laboratory medicine at Weill Cornell Medical College, said although fewer than 2 percent of men with prostate cancer present with neuroendocrine prostate cancer, the more common prostate adenocarcinoma can also evolve into a neuroendocrine prostate cancer, and the prognosis is grim.

"This is a highly lethal form of prostate cancer," said Rubin. "It is also rare enough that it's hard to get samples. This study is the largest of its kind, and it shows that we may be able to treat this highly aggressive disease."

Rubin and colleagues used next-generation RNA sequencing to profile samples of seven neuroendocrine prostate cancers, 30 prostate adenocarcinomas and five benign samples of prostate tissue.

They found that the genes AURKA and MYCN were overexpressed and amplified in 40 percent of neuroendocrine prostate cancers and in 5 percent of prostate adenocarcinomas.

Moreover, the researchers found that treatment with the investigational aurora kinase (AURKA) inhibitor PHA-739358 inhibited the growth of these neuroendocrine tumors.

Rubin said that PHA-739358 has been studied in prostate cancers before without success, but this may be due to the fact that previously studied prostate cancers were not neuroendocrine cancers.

"Prostate cancer is not a homogenous disease. We need to continue to sort out the aggressive disease from the indolent and treat accordingly," said Rubin.

The study was funded by the Prostate Cancer Foundation, the Ann and William Bresnan Foundation, the Early Detection Research Network and the Department of Defense.


Contact: Jeremy Moore
American Association for Cancer Research

Page: 1

Related biology news :

1. Scientists tackle the carbon conundrum
2. GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity
3. Scientists to use scent to control destructive rodent behavior
4. UA scientists find evidence of Roman period megadrought
5. San Diego Zoo scientists establish cell cultures of endangered frog
6. Structure, not scientists to blame for Los Alamos failings
7. Scientists discover new drug candidates for cystic fibrosis and other diseases
8. Gladstone scientists identify protein form linked to Huntingtons disease
9. Scientists chart gene expression in the brain across lifespan
10. Scientists measure dream content for the first time
11. A*STAR scientists first to identify stem cell key to lung regeneration
Post Your Comments:
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology: